The Health Technology Assessment research group is responsible for the research programmes in the field of health economics, in particular the so-called health technology assessment (HTA). This involves determining the implications of introducing, distributing and applying (new) medical technologies and assessing the resulting health gain. HTA aims to form a bridge between research and policy. Important research themes include:
- Decision-analytic modeling
- Late-phase studies & real-world evidence
- Multi-criteria decision analysis (MCDA)
- Preference measurement / Discrete choice evaluation (DCE) & Time trade off (TTO) studies.
Other relevant themes: Integrated care programs, medical devices, e-Health/telemedicine, transferability, value based health care.
Focus is on a wide range of diseases, including orphan diseases, oncology, chronic obstructive pulmonary disorder (COPD), diabetes, asthma, cardiovascular diseases, mental health, rheumatoid arthritis and multiple sclerosis.
The renowned Institute for Medical Technology Assessment (iMTA) is an independent company B.V. connected to ESHPM and the HTA research group.